BioMarin Inks $4.8B Amicus Buy As Patent Litigation Resolved
By Al Barbarino · December 19, 2025, 11:47 AM EST
BioMarin Pharmaceutical Inc. has agreed to acquire Amicus Therapeutics for $4.8 billion, in a deal bolstered by Amicus' settlement of patent litigation that secures U.S. exclusivity for its Galafold drug until...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login